Pharma's next cash cows could be specialized treatments
Pharmaceutical companies facing a steep patent cliff are concluding the key to future profits may be customized treatments tailored to patients' genes and lifestyles — not blockbusters aimed at large patient populations. Why it matters: The pivot could influence which diseases get treated in the decades to come, and…
Reported by Axios. We will add other newspapers as they cover it.
How the newspaper covers this story
Pharma's next cash cows could be specialized treatments
Pharmaceutical companies facing a steep patent cliff are concluding the key to future profits may be customized treatments tailored to patients' genes and lifestyles — not blockbusters aimed at large patient populations. Why it matters: The pivot could influence which diseases get treated in the decades to come, and…
